Sodium phosphate
ALIMENTARY TRACT AND METABOLISM
Also known as: disodium phosphate, sodium phosphate, dibasic, sodium phosphate, dibasic anhydrous, sodium phosphate, dibasic, heptahydrate, sodium phosphate, monobasic anhydrous, sodium phosphate, monobasic, anhydrous
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Sodium phosphate is a drug catalogued in DrugCentral. It was first approved by the FDA in 1983. DrugCentral lists 1 molecular target, including CA4. Recorded indications include Constipation.
- Molecular targets: CA4 (1 listed in DrugCentral).
- Indications: Constipation.
- ATC code: A06AD17 (Osmotically acting laxatives).
- Molecular formula: HNa2O4P; molecular weight 141.96 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Constipation
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Carbonic anhydrase 4 | CA4 | unknown | Ki 5.01 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1983-05-10 | FDA | — | HOSPIRA |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A06AD17 | ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Osmotically acting laxatives |
A06AG01 | ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Enemas |
B05XA09 | BLOOD AND BLOOD FORMING ORGANS › BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS › I.V. SOLUTION ADDITIVES › Electrolyte solutions |
V03AG05 | VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Drugs for treatment of hypercalcemia |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Appendicolith | 277.6 |
| Appendicitis | 212.2 |
| Cardiogenic shock | 166.2 |
| Blood phosphorus increased | 165.1 |
| Ventricular fibrillation | 145.6 |
| Hyperphosphataemia | 145.3 |
| Hypophosphataemia | 126.5 |
| Ascites | 125.9 |
| Blood uric acid increased | 125.1 |
| Aplastic anaemia | 122.9 |
| Myasthenia gravis | 122.7 |
| Abdominal distension | 114.3 |
Chemical structure
| Molecular formula | HNa2O4P |
|---|---|
| Molecular weight | 141.96 g/mol |
| CAS number | 7558-79-4 |
| InChIKey | — |
| PubChem CID | 24243 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Sodium phosphate used for?
DrugCentral lists the following indications for Sodium phosphate: Constipation.
How does Sodium phosphate work?
Its molecular targets in DrugCentral include CA4.
When was Sodium phosphate first approved?
Sodium phosphate was first approved by the FDA in 1983.
What is the chemical formula of Sodium phosphate?
Sodium phosphate has the molecular formula HNa2O4P and a molecular weight of 141.96 g/mol.
Browse: all drugs starting with S · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4219 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1060 — compound record and bioactivity
- PubChem CID 24243 — chemical identifiers
- DrugBank DB09449 — drug record
- FDA UNII SE337SVY37 — substance identity
- DailyMed: FDA labels for Sodium phosphate — current prescribing information (label search)
- UniProt P22748 (CA4) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.